Stocktoria
Bone Biologics Corp BBLG
Nasdaq · XNAS · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies · website · IPO 2015-11-27
Bone Biologics Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $1.1M | $2.1M | $6.9M | $1.6M | $82,044 |
| Operating income | -$3.2M | -$4.2M | -$9.4M | -$3.7M | -$1.1M |
| Income tax | — | — | — | — | $1,600 |
| Net income | -$3.1M | -$4.1M | -$8.9M | -$1.5M | -$1.6M |
| EPS (diluted) | $-2.65 | $-28.96 | $-34.01 | $-31.15 | — |
| Operating cash flow | -$2.7M | -$4.1M | -$9.6M | -$3.6M | -$1.2M |
| Cash & equivalents | — | — | — | $7.5M | $6.7M |
| Total assets | $5.8M | $3.9M | $3.7M | $8.5M | $6.7M |
| Total liabilities | $418,587 | $377,712 | $831,402 | $2.5M | $99,909 |
| Shareholders' equity | $5.4M | $3.5M | $2.9M | $5.9M | $6.6M |
Source: SEC EDGAR filings · CIK 0001419554 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.